indomethacin has been researched along with Hypertension, Portal in 37 studies
Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.
indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.
Hypertension, Portal: Abnormal increase of resistance to blood flow within the hepatic PORTAL SYSTEM, frequently seen in LIVER CIRRHOSIS and conditions with obstruction of the PORTAL VEIN.
| Excerpt | Relevance | Reference |
|---|---|---|
| " This study investigated whether the hyposensitivity to glypressin also exists in rats with common bile duct ligation (BDL) and whether the inhibition of PGI2 synthesis by indomethacin could potentiate the portal-hypotensive effect of glypressin in bleeding BDL rats." | 3.71 | Inhibition of prostacyclin by indomethacin ameliorates the splanchnic hyposensitivity to glypressin in haemorrhage-transfused common bile duct-ligated rats. ( Chan, CC; Chang, FY; Chen, CT; Chu, CJ; Hou, MC; Huang, HC; Lee, FY; Lee, SD; Lin, HC; Wang, SS; Wu, SL, 2001) |
| " Dose-response curves, the hemodynamic effects of prostacyclin (20 micrograms/kg) and its inhibitor indomethacin and measurements of plasma and urinary levels of 6-keto-prostaglandin F1 alpha were compared in three groups of six rats each: normal, with portal vein stenosis and with secondary biliary cirrhosis." | 3.68 | Role of prostacyclin in hemodynamic alterations in conscious rats with extrahepatic or intrahepatic portal hypertension. ( Cailmail, S; Lebrec, D; Moreau, R; Oberti, F; Pipy, B; Sogni, P, 1993) |
| " Dose-response curves to KCl (30-300 mM) were used to bypass G protein-coupled receptor mechanisms." | 1.42 | Neuropeptide Y restores non-receptor-mediated vasoconstrictive action in superior mesenteric arteries in portal hypertension. ( Dietrich, P; Hartl, J; Moleda, L; Müller-Schilling, M; Wiest, R, 2015) |
| "Portal hypertension was induced by partial portal vein ligation (PVL) in Sprague-Dawley rats." | 1.39 | Effects of simvastatin on the portal-systemic collateral vascular response to endothelin-1 and shunting degree in portal hypertensive rats. ( Chuang, CL; Hsin, IF; Hsu, SJ; Huang, HC; Lee, FY; Lee, JY; Lee, SD; Lin, HC; Wang, SS, 2013) |
| "Portal hypertension was induced by partial portal vein ligation (PVL)." | 1.31 | Effects of prostacyclin inhibition on splanchnic hyposensitivity to glypressin in a hemorrhage-transfused rat model of portal hypertension. ( Chan, CC; Chang, FY; Chu, CJ; Lee, FY; Lee, SD; Lin, HC; Wang, SS; Wu, SL, 2000) |
| "Portal hypertension is associated with increased hepatic and collateral resistance to an increased portal blood flow." | 1.31 | Endothelin-1 induces vasoconstriction on portal-systemic collaterals of portal hypertensive rats. ( Chan, CC; Chang, FY; Chen, CT; Chu, CJ; Huang, HC; Lee, FY; Lee, SD; Lin, HC; Wang, SS, 2001) |
| "Portal hypertension is associated with splanchnic hyperemia and increased plasma levels of prostacyclin." | 1.29 | Effects of nitric oxide and cyclooxygenase inhibition on splanchnic hemodynamics in portal hypertension. ( Burns, RC; Sitzmann, JV; Wu, Y, 1993) |
| "Indomethacin pretreatment (5 mg/kg, subcutaneously) caused a significant decrease in basal gastric mucosal blood flow of portal-hypertensive rats but did not modify this parameter in sham-operated animals." | 1.29 | Involvement of nitric oxide and prostaglandins in gastric mucosal hyperemia of portal-hypertensive anesthetized rats. ( Bosch, J; Casadevall, M; Marroni, N; Panés, J; Piqué, JM; Whittle, BJ, 1993) |
| "Portal hypertension was produced in male Sprague-Dawley rats by two-staged ligation of the portal vein." | 1.28 | The effect of portal hypertension on indomethacin-induced small intestinal ulceration in the rat. ( Chung, K; Erickson, RA; Jonas, GM, 1991) |
| " Dose-response curves were obtained and statistical comparisons were based on the dose of norepinephrine producing 50% of maximal Rsma response (ED50)." | 1.28 | Prostacyclin mediates splanchnic vascular response to norepinephrine in portal hypertension. ( Li, SS; Lin, PW; Sitzmann, JV, 1989) |
| "Chronic portal hypertension was induced by a two-stage complete portal vein occlusion procedure." | 1.27 | Gastric mucosal blood flow and acid secretion in portal hypertensive rats. ( Guth, PH; Kitahora, T; Leung, FW; Pique, JM; Sarfeh, IJ; Tarnawski, A, 1988) |
| "Portal hypertension was produced experimentally in rats by partial constriction of the portal vein." | 1.27 | Lack of effect of indomethacin on systemic and splanchnic haemodynamics in portal hypertensive rats. ( Blanchart, A; Fernández-Muñoz, D; Hernando, L; Hernando, N; López-Novoa, JM, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (10.81) | 18.7374 |
| 1990's | 16 (43.24) | 18.2507 |
| 2000's | 14 (37.84) | 29.6817 |
| 2010's | 3 (8.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hsu, SJ | 1 |
| Wang, SS | 9 |
| Hsin, IF | 1 |
| Huang, HC | 7 |
| Lee, FY | 11 |
| Lee, JY | 2 |
| Lin, HC | 10 |
| Chuang, CL | 1 |
| Lee, SD | 11 |
| Hartl, J | 1 |
| Dietrich, P | 1 |
| Moleda, L | 1 |
| Müller-Schilling, M | 1 |
| Wiest, R | 1 |
| Xu, J | 2 |
| Cao, H | 3 |
| Liu, H | 2 |
| Wu, ZY | 3 |
| Chang, CC | 3 |
| Chan, CC | 6 |
| Chang, FY | 8 |
| Hou, MC | 4 |
| Chen, XS | 1 |
| Qiu, JF | 2 |
| Tai, CC | 2 |
| Lay, CS | 1 |
| May, CM | 1 |
| Tsai, YT | 1 |
| Chien, S | 1 |
| Sinchon, S | 1 |
| Aller, MA | 1 |
| Arias, J | 1 |
| Meng, FB | 1 |
| Chen, YC | 1 |
| Eizayaga, FX | 1 |
| Aguejouf, O | 1 |
| Desplat, V | 1 |
| Belon, P | 1 |
| Doutremepuich, C | 1 |
| Wu, Y | 1 |
| Burns, RC | 1 |
| Sitzmann, JV | 5 |
| Casadevall, M | 2 |
| Panés, J | 1 |
| Piqué, JM | 3 |
| Marroni, N | 1 |
| Bosch, J | 2 |
| Whittle, BJ | 1 |
| Oberti, F | 1 |
| Sogni, P | 3 |
| Cailmail, S | 2 |
| Moreau, R | 3 |
| Pipy, B | 1 |
| Lebrec, D | 3 |
| Fernández, M | 1 |
| García-Pagán, JC | 1 |
| Mourelle, MI | 1 |
| Rodés, J | 1 |
| Yin, J | 1 |
| Leng, X | 1 |
| Zhu, J | 1 |
| Sabry, S | 1 |
| Gadano, A | 1 |
| Dinh-Xuan, AT | 1 |
| García-Estañ, J | 1 |
| Atucha, NM | 1 |
| Groszmann, RJ | 1 |
| Gadano, AC | 1 |
| Yang, S | 1 |
| Nepveux, P | 1 |
| Couturier, D | 1 |
| Yamamoto, S | 1 |
| Burman, HP | 1 |
| O'Donnell, CP | 1 |
| Cahill, PA | 1 |
| Robotham, JL | 1 |
| Lamarque, D | 1 |
| Dutreuil, C | 1 |
| Dhumeaux, D | 1 |
| Delchier, JC | 1 |
| Tsugawa, K | 1 |
| Hashizume, M | 1 |
| Migou, S | 1 |
| Kishihara, F | 1 |
| Kawanaka, H | 1 |
| Tomikawa, M | 1 |
| Sugimachi, K | 1 |
| Chu, CJ | 4 |
| Lai, IN | 1 |
| Wu, SL | 2 |
| Garcia, N | 1 |
| Járai, Z | 1 |
| Mirshahi, F | 1 |
| Kunos, G | 1 |
| Sanyal, AJ | 1 |
| Chen, CT | 2 |
| Yang, YY | 1 |
| Huang, YT | 1 |
| Lee, TY | 1 |
| Lee, WC | 1 |
| Mentz, P | 1 |
| Giessler, C | 1 |
| Wu, YP | 1 |
| Li, SS | 3 |
| Campbell, KA | 1 |
| Jonas, GM | 1 |
| Erickson, RA | 1 |
| Chung, K | 1 |
| Adkinson, NF | 1 |
| Bulkley, GB | 1 |
| Mitchell, MC | 1 |
| Campbell, K | 1 |
| Lin, PW | 1 |
| Leung, FW | 1 |
| Kitahora, T | 1 |
| Sarfeh, IJ | 1 |
| Tarnawski, A | 1 |
| Guth, PH | 1 |
| Blanchart, A | 1 |
| Hernando, N | 1 |
| Fernández-Muñoz, D | 1 |
| Hernando, L | 1 |
| López-Novoa, JM | 1 |
37 other studies available for indomethacin and Hypertension, Portal
| Article | Year |
|---|---|
Effects of simvastatin on the portal-systemic collateral vascular response to endothelin-1 and shunting degree in portal hypertensive rats.
Topics: Animals; Collateral Circulation; Cyclooxygenase Inhibitors; Endothelin-1; Hemodynamics; Hydroxymethy | 2013 |
Neuropeptide Y restores non-receptor-mediated vasoconstrictive action in superior mesenteric arteries in portal hypertension.
Topics: Animals; Cyclooxygenase Inhibitors; Hemodynamics; Hypertension, Portal; Indomethacin; Male; Mesenter | 2015 |
Role of nitric oxide synthase and cyclooxygenase in hyperdynamic splanchnic circulation of portal hypertension.
Topics: Animals; Aorta, Abdominal; Cyclooxygenase Inhibitors; Disease Models, Animal; Epoprostenol; Hyperten | 2008 |
Pravastatin administration does not induce detrimental effects on hemodynamics and collaterals of portal hypertensive rats.
Topics: Animals; Collateral Circulation; Cyclooxygenase Inhibitors; Disease Models, Animal; Dose-Response Re | 2010 |
Effects of endothelin-1 on portal-systemic collaterals of common bile duct-ligated cirrhotic rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Collateral Circulation; C | 2004 |
Role of PGI2 in the formation and maintenance of hyperdynamic circulatory state of portal hypertensive rats.
Topics: Animals; Anticoagulants; Cyclooxygenase Inhibitors; Enzyme Inhibitors; Epoprostenol; Heparin; Hypert | 2005 |
Effects of norepinephrine and acetylcholine on portal-systemic collaterals of common bile duct-ligated cirrhotic rat.
Topics: Acetylcholine; Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antihypertens | 2005 |
Effect of verapamil on nitric oxide synthase in a portal vein-ligated rat model: role of prostaglandin.
Topics: Animals; Epoprostenol; Hemodynamics; Hypertension, Portal; Indomethacin; Male; Nitric Oxide Synthase | 2006 |
Portal systemic collateral development: is it a trophic adaptation mechanism to hepatic deprivation?
Topics: Acetylcholine; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Collateral | 2006 |
Influence of nitric oxide synthase and cyclooxygenase blockade on expression of cyclooxygenase and hemodynamics in rats with portal hypertension.
Topics: Animals; Cyclooxygenase 1; Epoprostenol; Gene Expression; Hypertension, Portal; Indomethacin; Male; | 2006 |
Chronic cyclooxygenase blockade enhances the vasopressin responsiveness in collaterals of portal hypertensive rats.
Topics: Animals; Arginine Vasopressin; Blood Pressure; Collateral Circulation; Cyclooxygenase Inhibitors; Di | 2006 |
Modifications produced by indomethacin and L-NAME in the effect of ultralow-dose aspirin on platelet activity in portal hypertension.
Topics: Animals; Aspirin; Blood Coagulation Tests; Cyclooxygenase Inhibitors; Disease Models, Animal; Drug I | 2006 |
Effects of nitric oxide and cyclooxygenase inhibition on splanchnic hemodynamics in portal hypertension.
Topics: Animals; Arginine; Epoprostenol; Hemodynamics; Hypertension, Portal; Indomethacin; Male; NG-Nitroarg | 1993 |
Involvement of nitric oxide and prostaglandins in gastric mucosal hyperemia of portal-hypertensive anesthetized rats.
Topics: Anesthesia, General; Animals; Arginine; Blood Pressure; Gastric Mucosa; Hypertension, Portal; Indome | 1993 |
Role of prostacyclin in hemodynamic alterations in conscious rats with extrahepatic or intrahepatic portal hypertension.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Blood Pressure; Cardiac Output; Common Bile Duct; Dose-Respon | 1993 |
Acute and chronic cyclooxygenase blockage in portal-hypertensive rats: influence in nitric oxide biosynthesis.
Topics: Animals; Arginine; Blood Pressure; Cyclooxygenase Inhibitors; Enzyme Inhibitors; Epoprostenol; Hyper | 1996 |
[Plasma prostacyclin (PGI2) levels in peripheral venous, arterial and portal venous blood in cirrhotic patients with portal hypertension and their clinical implication].
Topics: Adult; Aged; Cyclooxygenase Inhibitors; Epoprostenol; Female; Humans; Hypertension, Portal; Indometh | 1995 |
Hyporeactivity of mesenteric resistance arteries in portal hypertensive rats.
Topics: Acetylcholine; Animals; Dose-Response Relationship, Drug; Hypertension, Portal; Indomethacin; Male; | 1996 |
Renal response to methoxamine in portal hypertensive rats: role of prostaglandins and nitric oxide.
Topics: Acetylcholine; Animals; Enzyme Inhibitors; Hypertension, Portal; In Vitro Techniques; Indomethacin; | 1996 |
Endothelial calcium-calmodulin dependent nitric oxide synthase in the in vitro vascular hyporeactivity of portal hypertensive rats.
Topics: Animals; Aorta, Thoracic; Calcium-Calmodulin-Dependent Protein Kinases; Cyclooxygenase Inhibitors; D | 1997 |
Endothelin causes portal and pulmonary hypertension in porcine endotoxemic shock.
Topics: Analysis of Variance; Animals; Bosentan; Cyclooxygenase Inhibitors; Endothelin Receptor Antagonists; | 1997 |
Increased gastric bicarbonate secretion in portal hypertensive anesthetized rats: role of prostaglandins and nitric oxide.
Topics: Anesthesia; Animals; Bicarbonates; Blood Pressure; Capillary Permeability; Cyclooxygenase Inhibitors | 1997 |
A selective cyclo-oxygenase-2 inhibitor, NS-398, may improve portal hypertension without inducing gastric mucosal injury.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibito | 1999 |
Effects of vasopressin on portal-systemic collaterals in portal hypertensive rats: role of nitric oxide and prostaglandin.
Topics: Animals; Collateral Circulation; Deamino Arginine Vasopressin; Dose-Response Relationship, Drug; Hyp | 1999 |
Effects of prostacyclin inhibition on splanchnic hyposensitivity to glypressin in a hemorrhage-transfused rat model of portal hypertension.
Topics: Analysis of Variance; Animals; Antihypertensive Agents; Blood Transfusion; Cyclooxygenase Inhibitors | 2000 |
Systemic and portal hemodynamic effects of anandamide.
Topics: Animals; Arachidonic Acids; Blood Pressure; Calcium Channel Blockers; Cannabinoids; Cardiac Output; | 2001 |
Inhibition of prostacyclin by indomethacin ameliorates the splanchnic hyposensitivity to glypressin in haemorrhage-transfused common bile duct-ligated rats.
Topics: Animals; Blood Transfusion; Common Bile Duct; Drug Interactions; Epoprostenol; Hemorrhage; Hypertens | 2001 |
Endothelin-1 induces vasoconstriction on portal-systemic collaterals of portal hypertensive rats.
Topics: Animals; Collateral Circulation; Cyclooxygenase Inhibitors; Drug Combinations; Endothelin Receptor A | 2001 |
Adaptive vasodilatory response after octreotide treatment.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Aorta; Blotting, Western; Cyclooxygenase Inhibitors; Dose-Res | 2001 |
Biosynthesis of TXB2 and 6-oxo-PGF1 alpha in the heart and other tissues under pathophysiological conditions.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Aqueous Humor; Brain Diseases; Child; Gastric Mucosa; Gastrit | 1992 |
Modulation of splanchnic vascular sensitivity to angiotensin II.
Topics: Angiotensin II; Animals; Cyclooxygenase Inhibitors; Disease Models, Animal; Epoprostenol; Hypertensi | 1991 |
The effect of portal hypertension on indomethacin-induced small intestinal ulceration in the rat.
Topics: Animals; Duodenal Ulcer; Hypertension, Portal; Indomethacin; Intestinal Mucosa; Male; Rats; Rats, In | 1991 |
Evidence for role of prostacyclin as a systemic hormone in portal hypertension.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Aorta, Abdominal; Epoprostenol; Hypertension, Portal; Indomet | 1991 |
Role of prostacyclin in the splanchnic hyperemia contributing to portal hypertension.
Topics: Animals; Cyclooxygenase Inhibitors; Epoprostenol; Hyperemia; Hypertension, Portal; Indomethacin; Mal | 1989 |
Prostacyclin mediates splanchnic vascular response to norepinephrine in portal hypertension.
Topics: Animals; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Epoprostenol; Hypertension, Po | 1989 |
Gastric mucosal blood flow and acid secretion in portal hypertensive rats.
Topics: Animals; Blood Pressure; Dinoprostone; Gastric Acid; Gastric Mucosa; Hypertension, Portal; Indometha | 1988 |
Lack of effect of indomethacin on systemic and splanchnic haemodynamics in portal hypertensive rats.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Dinoprostone; Hemodynamics; Hypertension, Portal; Indomethaci | 1985 |